Prakash, A., Offin, M., Sharma, M. R., Spira, A. I., Lee, S., Baggstrom, M. Q., Lepissier, A., Seif, V., Hua, Z., Mody, K., Luo, J., Niu, J. (2026). A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BRAF and other selected RAS/MAPK mutation positive malignancies.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps857